Evidence-based articles on peptides, GLP-1, longevity, and metabolic health.
A comprehensive look at the latest 2026 research on GLP-1 receptor agonists including semaglutide and tirzepatide — covering weight loss efficacy, cardiovascular benefits, and emerging neuroprotective properties.